Variant · Amplification
CCND2 Amplification
CI-VAR-00000241Explore in graph →CIViC 2746
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31302234
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Squamous Cell Carcinoma1 | ||||||||
| CCND2 Amplification | Palbociclib | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID7406In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC) PMID 31302234 · Edelman et al., 2019 · Open in CIViC | civic |
| Malignant Neoplasm1 | ||||||||
| CCND1 Amplification OR CCND2 Amplification OR CCND3 Amplification | Palbociclib | Predictive | B | Does Not Support Sensitivity Response | 4 | accepted | EID11673This Phase 2 NCI-MATCH Trial subprotocol Z1B was conducted in 32 patients with either CCND1, 2 or 3 amplification, and were treated with Palbociclib. Squamous cell lung cancer (n=5), adenocarcinoma of… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available